UCB (OTCMKTS:UCBJY) Stock Price Passes Above 50 Day Moving Average – What’s Next?

Shares of UCB SA (OTCMKTS:UCBJY) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $143.16 and traded as high as $147.94. UCB shares last traded at $146.91, with a volume of 25,401 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on UCBJY shares. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research report on Thursday, June 11th. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a report on Monday, June 22nd. Finally, Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, UCB currently has a consensus rating of “Hold”.

UCB Stock Performance

The company’s 50-day moving average price is $143.16 and its 200 day moving average price is $147.77. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.